Stay updated on Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial

Sign up to get notified when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:32:36.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the safety demonstration study of Tildrakizumab for subjects with Psoriatic Arthritis who have previously completed the study with Tildrakizumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:14.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying both inclusion and exclusion criteria, whereas previously no information was provided.
    Difference
    27%
    Check dated 2024-05-22T20:57:21.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:21:25.000Z thumbnail image

Stay in the know with updates to Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.